IP Library Granted Patent US 8,058,247
Granted Patent B2
US 8,058,247 · App. 12/378,172 · Granted Nov 15, 2011

Antibacterial agent and therapeutic agent for johne's disease containing the same

Assignees: Microbial Chemistry Research Foundation; Meiji Seika Kaisha, Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,058,247
App. No.
12/378,172
Granted
Nov 15, 2011
Kind
B2
Abstract

An antibacterial agent having high antibacterial activity against Mycobacterium avium subsp. paratuberculosis is provided. Specifically, the antibacterial agent of the present invention having high antibacterial activity against Mycobacterium avium subsp. paratuberculosis is a caprazamycin derivative represented, for example, by the following general formula (II): wherein Me is a methyl group; and R 1 is a straight or substantially straight chain alkyl group having 5 to 21 carbon atoms, a straight or substantially straight chain alkenyl group having 5 to 21 carbon atoms, a cycloalkyl group having 5 to 12 carbon atoms, or a phenyl group substituted at the para-position with a straight chain alkyl group having 1 to 14 carbon atoms, a straight chain alkoxy group having 1 to 9 carbon atoms or a cycloalkyl group having 5 to 12 carbon atoms.

Claims (39)

1. A method for inhibiting growth of Mycobacterium avium subsp. paratuberculosis , comprising applying a caprazamycin derivative represented by one of the following general formula (II), (III), (V), (VI) or (VII) to Mycobacterium avium subsp. paratuberculosis :

wherein Me is a methyl group; and R 1 is a straight or substantially straight chain alkyl group having 5 to 21 carbon atoms, a straight or substantially straight chain alkenyl group having 5 to 21 carbon atoms, a cycloalkyl group having 5 to 12 carbon atoms, or a phenyl group substituted at the para-position with a straight chain alkyl group having 1 to 14 carbon atoms, a straight chain alkoxy group having 1 to 9 carbon atoms or a cycloalkyl group having 5 to 12 carbon atoms;

wherein Me is a methyl group; and R 2 is a straight or substantially straight chain alkyl group having 5 to 21 carbon atoms, a straight or substantially straight chain alkenyl group having 5 to 21 carbon atoms, or an alkynyl group having 5 to 21 carbon atoms;

wherein Me is a methyl group; and R 3 is a straight or substantially straight chain alkyl group having 5 to 21 carbon atoms, a straight or substantially straight chain alkenyl group having 5 to 21 carbon atoms, or a cycloalkyl group having 5 to 12 carbon atoms;

wherein Me is a methyl group; R 3 is a straight or substantially straight chain alkyl group having 5 to 21 carbon atoms, a straight or substantially straight chain alkenyl group having 5 to 21 carbon atoms, or a cycloalkyl group having 5 to 12 carbon atoms; and R 4 is a straight or substantially straight chain alkyl group having 5 to 21 carbon atoms, a straight or substantially straight chain alkenyl group having 5 to 21 carbon atoms, or an alkynyl group having 5 to 21 carbon atoms; and

wherein Me is a methyl group; R 4 is a straight or substantially straight chain alkyl group having 5 to 21 carbon atoms, a straight or substantially straight chain alkenyl group having 5 to 21 carbon atoms, or an alkynyl group having 5 to 21 carbon atoms; and R 5 is a hydrogen atom, or a straight or substantially straight chain alkyl group having 1 to 21 carbon atoms.

2. The method for inhibiting growth of Mycobacterium avium subsp. paratuberculosis according to claim 1 , wherein the caprazamycin derivative is represented by the following general formula (II):

wherein Me is a methyl group; and R 1 is a straight or substantially straight chain alkyl group having 5 to 21 carbon atoms, a straight or substantially straight chain alkenyl group having 5 to 21 carbon atoms, a cycloalkyl group having 5 to 12 carbon atoms, or a phenyl group substituted at the para-position with a straight chain alkyl group having 1 to 14 carbon atoms, a straight chain alkoxy group having 1 to 9 carbon atoms, or a cycloalkyl group having 5 to 12 carbon atoms.

3. The method for inhibiting growth of Mycobacterium avium subsp. paratuberculosis according to claim 2 , wherein R 1 is a straight chain alkyl group having 8 to 16 carbon atoms.

4. The method for inhibiting growth of Mycobacterium avium subsp. paratuberculosis according to claim 2 , wherein R 1 is a cycloalkyl group having 5 to 12 carbon atoms, or a phenyl group substituted at the para-position with a straight chain alkyl group having 1 to 14 carbon atoms, a straight chain alkoxy group having 1 to 9 carbon atoms or a cycloalkyl group having 5 to 12 carbon atoms.

5. The method for inhibiting growth of Mycobacterium avium subsp. paratuberculosis according to claim 1 , wherein the caprazamycin derivative is represented by the following general formula (III):

wherein Me is a methyl group; and R 2 is a straight or substantially straight chain alkyl group having 5 to 21 carbon atoms, a straight or substantially straight chain alkenyl group having 5 to 21 carbon atoms, or an alkynyl group having 5 to 21 carbon atoms.

6. The method for inhibiting growth of Mycobacterium avium subsp. paratuberculosis according to claim 1 , wherein the caprazamycin derivative is represented by the following general formula (V):

wherein Me is a methyl group; and R 3 is a straight or substantially straight chain alkyl group having 5 to 21 carbon atoms, a straight or substantially straight chain alkenyl group having 5 to 21 carbon atoms, or a cycloalkyl group having 5 to 12 carbon atoms.

7. The method for inhibiting growth of Mycobacterium avium subsp. paratuberculosis according to claim 1 , wherein the caprazamycin derivative is represented by the following general formula (VI):

wherein Me is a methyl group; R 3 is a straight or substantially straight chain alkyl group having 5 to 21 carbon atoms, a straight or substantially straight chain alkenyl group having 5 to 21 carbon atoms, or a cycloalkyl group having 5 to 12 carbon atoms; and R 4 is a straight or substantially straight chain alkyl group having 5 to 21 carbon atoms, a straight or substantially straight chain alkenyl group having 5 to 21 carbon atoms, or an alkynyl group having 5 to 21 carbon atoms.

8. The method for inhibiting growth of Mycobacterium avium subsp. paratuberculosis according to claim 1 , wherein the caprazamycin derivative is represented by the following general formula (VII):

wherein Me is a methyl group; R 4 is a straight or substantially straight chain alkyl group having 5 to 21 carbon atoms, a straight or substantially straight chain alkenyl group having 5 to 21 carbon atoms, or an alkynyl group having 5 to 21 carbon atoms; and R 5 is a hydrogen atom, or a straight or substantially straight chain alkyl group having 1 to 21 carbon atoms.

9. The method for inhibiting growth of Mycobacterium avium subsp. paratuberculosis according to claim 8 , wherein R 4 is a straight chain alkyl group having 8 to 16 carbon atoms; and R 5 is a hydrogen atom.

10. A method for treatment of Mycobacterium avium subsp. paratuberculosis infection, comprising administrating a caprazamycin derivative represented by one of the following general formulae (II), (III), (V), (VI), or (VII) to a subject having Mycobacterium avium subsp. paratuberculosis infection:

wherein Me is a methyl group; and R 1 is a straight or substantially straight chain alkyl group having 5 to 21 carbon atoms, a straight or substantially straight chain alkenyl group having 5 to 21 carbon atoms, a cycloalkyl group having 5 to 12 carbon atoms, or a phenyl group substituted at the para-position with a straight chain alkyl group having 1 to 14 carbon atoms; a straight chain alkoxy group having 1 to 9 carbon atoms or a cycloalkyl group having 5 to 12 carbon atoms;

wherein Me is a methyl group; and R 2 is a straight or substantially straight chain alkyl group having 5 to 21 carbon atoms, a straight or substantially straight chain alkenyl group having 5 to 21 carbon atoms, or an alkynyl group having 5 to 21 carbon atoms;

wherein Me is a methyl group; and R 3 is a straight or substantially straight chain alkyl group having 5 to 21 carbon atoms, a straight or substantially straight chain alkenyl group having 5 to 21 carbon atoms, or a cycloalkyl group having 5 to 12 carbon atoms;

wherein Me is a methyl group; R 3 is a straight or substantially straight chain alkyl group having 5 to 21 carbon atoms, a straight or substantially straight chain alkenyl group having 5 to 21 carbon atoms, or a cycloalkyl group having 5 to 12 carbon atoms; and R 4 is a straight or substantially straight chain alkyl group having 5 to 21 carbon atoms, a straight or substantially straight chain alkenyl group having 5 to 21 carbon atoms, or an alkynyl group having 5 to 21 carbon atoms; and

wherein Me is a methyl group; R 4 is a straight or substantially straight chain alkyl group having 5 to 21 carbon atoms, a straight or substantially straight chain alkenyl group having 5 to 21 carbon atoms, or an alkynyl group having 5 to 21 carbon atoms; and R 5 is a hydrogen atom, or a straight or substantially straight chain alkyl group having 1 to 21 carbon atoms.

11. The method for treatment of Mycobacterium avium subsp. paratuberculosis infection according to claim 10 , wherein the caprazamycin derivative is represented by the following general formula

wherein Me is a methyl group; and R 1 is a straight or substantially straight chain alkyl group having 5 to 21 carbon atoms, a straight or substantially straight chain alkenyl group having 5 to 21 carbon atoms, a cycloalkyl group having 5 to 12 carbon atoms, or a phenyl group substituted at the para-position with a straight chain alkyl group having 1 to 14 carbon atoms, a straight chain alkoxy group having 1 to 9 carbon atoms, or a cycloalkyl group having 5 to 12 carbon atoms.

12. The method for treatment of Mycobacterium avium subsp. paratuberculosis infection according to claim 11 , wherein R 1 is a straight chain alkyl group having 8 to 16 carbon atoms.

13. The method for treatment of Mycobacterium avium subsp. paratuberculosis infection according to claim 11 , wherein R 1 is a cycloalkyl group having 5 to 12 carbon atoms, or a phenyl group substituted at the para-position with a straight chain alkyl group having 1 to 14 carbon atoms, a straight chain alkoxy group having 1 to 9 carbon atoms or a cycloalkyl group having 5 to 12 carbon atoms.

14. The method for treatment of Mycobacterium avium subsp. paratuberculosis infection according to claim 10 , wherein the caprazamycin derivative is represented by the following general formula

wherein Me is a methyl group; and R 2 is a straight or substantially straight chain alkyl group having 5 to 21 carbon atoms, a straight or substantially straight chain alkenyl group having 5 to 21 carbon atoms, or an alkynyl group having 5 to 21 carbon atoms.

15. The method for treatment of Mycobacterium avium subsp. paratuberculosis infection according to claim 10 , wherein the caprazamycin derivative is represented by the following general formula

wherein Me is a methyl group; and R 3 is a straight or substantially straight chain alkyl group having 5 to 21 carbon atoms, a straight or substantially straight chain alkenyl group having 5 to 21 carbon atoms, or a cycloalkyl group having 5 to 12 carbon atoms.

16. The method for treatment of Mycobacterium avium subsp. paratuberculosis infection according to claim 10 , wherein the caprazamycin derivative is represented by the following general formula

wherein Me is a methyl group; R 3 is a straight or substantially straight chain alkyl group having 5 to 21 carbon atoms, a straight or substantially straight chain alkenyl group having 5 to 21 carbon atoms, or a cycloalkyl group having 5 to 12 carbon atoms; and R 4 is a straight or substantially straight chain alkyl group having 5 to 21 carbon atoms, a straight or substantially straight chain alkenyl group having 5 to 21 carbon atoms, or an alkynyl group having 5 to 21 carbon atoms.

17. The method for treatment of Mycobacterium avium subsp. paratuberculosis infection according to claim 10 , wherein the caprazamycin derivative is represented by the following general formula (VII):

wherein Me is a methyl group; R 4 is a straight or substantially straight chain alkyl group having 5 to 21 carbon atoms, a straight or substantially straight chain alkenyl group having 5 to 21 carbon atoms, or an alkynyl group having 5 to 21 carbon atoms; and R 5 is a hydrogen atom, or a straight or substantially straight chain alkyl group having 1 to 21 carbon atoms.

18. The method for treatment of Mycobacterium avium subsp. paratuberculosis infection according to claim 17 , wherein R 4 is a straight chain alkyl group having 8 to 16 carbon atoms; and R 5 is a hydrogen atom.

19. The method for treatment of Mycobacterium avium subsp. paratuberculosis infection according to claim 10 , wherein the Mycobacterium avium subsp. paratuberculosis infection includes Johne's disease.

Assignments (2)
CHANGE OF NAME Recorded Mar 20, 2014
From: MEIJI SEIKA KAISHA, LTD.
To: MEIJI SEIKA PHARMA CO., LTD.
Reel/Frame 032482/0204 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2009
From: TAKAHASHI, YOSHIAKI; IGARASHI, MASAYUKI
To: MICROBIAL CHEMISTRY RESEARCH FOUNDATION; MEIJI SEIKA KAISHA, LTD.
Reel/Frame 022636/0489 →
Priority Claims (1)
JP 2006-221723 · Aug 15, 2006 · national
Continuity (2)
Continuation PCTJP2007065606 · Aug 9, 2007
Related Publication 20090209744A1 · Aug 20, 2009